8.69 USD
▼-2.06-19.16%
盘后 13.52 0.00%
2026-11-20
市值
$9.64M
市盈率
—
EPS
-1.23
股息率
—
52 周区间
8.47 – 72.60
成交量
11.72K
Beta
3.30
目标价
250.00
52W 低 8.4752W 高 72.60
价格走势
公司简介
Jasper Therapeutics, Inc., a clinical stage biotechnology company, focuses on the design and development of therapies to treat immune-mediated diseases. Its products in various stages of development include KP-104, a dual-complement inhibitor for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) which is in Phase 2; Briquilimab is an anti-KIT antibody, which has demonstrated clinical results as a conditioning agent for stem cell transplant and mast cell mediated diseases, such as chronic urticarias and allergic asthma; and KP-701, a no...